Alimera Sciences Inc/ US0162592028 /
2024-05-15 10:00:00 PM | Chg. -0.0100 | Volume | Bid10:09:40 AM | Ask10:09:40 AM | High | Low |
---|---|---|---|---|---|---|
3.2700USD | -0.30% | 61,001 Turnover: 171,371.2020 |
1.3200Bid Size: 100 | 5.1900Ask Size: 100 | 3.4551 | 3.2550 |
GlobeNewswire
05-07
Alimera Announces Scientific Data Highlighting YUTIQ® to be Presented at Upcoming Association for Re...
GlobeNewswire
04-30
Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corpora...
GlobeNewswire
03-19
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRC...
GlobeNewswire
02-29
Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and...
GlobeNewswire
02-08
The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provi...
GlobeNewswire
01-02
Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Na...
GlobeNewswire
2023-12-12
Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Und...
GlobeNewswire
2023-11-01
EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporat...
GlobeNewswire
2023-10-31
Alimera Announces Scientific Data Highlighting ILUVIEN® To Be Presented at the American Academy of O...
GlobeNewswire
2023-10-16
Alimera Sciences to Report Third Quarter 2023 Financial Results on October 26, 2023, and Provide Cor...
GlobeNewswire
2023-10-11
Alimera Announces Multiple Presentations Highlighting ILUVIEN® and YUTIQ® Data at Retina Society Ann...
GlobeNewswire
2023-09-11
EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 i...
GlobeNewswire
2023-09-05
Alimera Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference